Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study.
Ponzano M, Schiavetti I, Bergamaschi R, Pisoni E, Bellavia A, Mallucci G, Carmisciano L, Inglese M, Cordioli C, Marfia GA, Cocco E, Immovilli P, Pesci I, Scandellari C, Cavalla P, Radaelli M, Vianello M, Vitetta F, Montepietra S, Amato MP, Fioretti C, Filippi M, Sartori A, Caleri F, Clerico M, Gallo A, Conte A, Clerici R, De Luca G, Boneschi FM, Cantello R, Calabrese M, Tortorella C, Rovaris M, Verrengia EP, Patti F, Morra VB, Salvetti M, Sormani MP; MuSC-19 Study Group. Ponzano M, et al. Among authors: salvetti m. Mult Scler Relat Disord. 2022 Dec;68:104243. doi: 10.1016/j.msard.2022.104243. Epub 2022 Oct 20. Mult Scler Relat Disord. 2022. PMID: 36288659 Free PMC article.
Genetic burden of common variants in progressive and bout-onset multiple sclerosis.
Sorosina M, Brambilla P, Clarelli F, Barizzone N, Lupoli S, Guaschino C, Osiceanu AM, Moiola L, Ghezzi A, Coniglio G, Patti F, Mancardi G, Manunta P, Glorioso N, Guerini FR, Bergamaschi R, Perla F; PROGRESSO; PROGEMUS; Martinelli V, Cusi D, Leone M, Comi G, D'Alfonso S, Martinelli-Boneschi F. Sorosina M, et al. Mult Scler. 2014 Jun;20(7):802-11. doi: 10.1177/1352458513512707. Epub 2013 Nov 25. Mult Scler. 2014. PMID: 24277324
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.
Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S; Italian Multiple Sclerosis Study group. Bertolotto A, et al. Among authors: salvetti m. Neurol Sci. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29. Neurol Sci. 2014. PMID: 24374787
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Landi D, et al. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22. Neurology. 2017. PMID: 28228569 Free article.
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M. Prosperini L, et al. Among authors: salvetti m. Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6. Neurology. 2018. PMID: 29875218 Clinical Trial.
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA. Landi D, et al. Among authors: salvetti m. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3. J Neurol Neurosurg Psychiatry. 2018. PMID: 29970387
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C. Mirabella M, et al. Among authors: salvetti m. CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3. CNS Drugs. 2018. PMID: 30022464
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
597 results